Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial
Titel:
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial
Auteur:
Kater, Arnon P Levin, Mark-David Dubois, Julie Kersting, Sabina Enggaard, Lisbeth Veldhuis, Gerrit J Mous, Rogier Mellink, Clemens H M van der Kevie-Kersemaekers, Anne-Marie F Dobber, Johan A Poulsen, Christian B Frederiksen, Henrik Janssens, Ann Schjødt, Ida Dompeling, Ellen C Ranti, Juha Brieghel, Christian Mattsson, Mattias Bellido, Mar Tran, Hoa T T Nasserinejad, Kazem Niemann, Carsten U